A Lectin-EGF antibody promotes regulatory T cells and attenuates nephrotoxic nephritis via DC-SIGN on dendritic cells by Minchao Cai et al.
Cai et al. Journal of Translational Medicine 2013, 11:103
http://www.translational-medicine.com/content/11/1/103RESEARCH Open AccessA Lectin-EGF antibody promotes regulatory T
cells and attenuates nephrotoxic nephritis via
DC-SIGN on dendritic cells
Minchao Cai1,2†, Jing Wu1†, Chaoming Mao3,4†, Jianmin Ren1, Pu Li1, Xiao Li2, Jiuchang Zhong5, Chundi Xu1
and Tong Zhou1,2*Abstract
Background: Interactions between dendritic cells (DCs) and T cells play a critical role in the development of
glomerulonephritis, which is a common cause of chronic kidney disease. DC-specific intercellular adhesion
molecule-3-grabbing non-integrin (DC-SIGN), an immune-regulating molecule of the C-type lectin family, is mainly
expressed on DCs and mediates DC adhesion and migration, inflammation, activation of primary T cells. DC-SIGN
triggers immune responses and is involved in the immune escape of pathogens and tumours. In addition, ligation
of DC-SIGN on DCs actively primes DCs to induce Tregs. Under certain conditions, DC-SIGN signalling may result in
inhibition of DC maturation, by promoting regulatory T cell (Treg) function and affecting Th1/Th2 bias.
Methods: A rat model of nephrotoxic nephritis was used to investigate the therapeutic effects of an anti-lectin
-epidermal growth factor (EGF) antibody on glomerulonephritis. DCs were induced by human peripheral blood
mononuclear cells in vitro. The expression of DC surface antigens were detected using flow cytometry; the
levels of cytokines were detected by ELISA and qPCR, respectively; the capability of DCs to stimulate T cell
proliferation was examined by mixed lymphocyte reaction; PsL-EGFmAb targeting to DC-SIGN on DCs was
identified by immunoprecipitation.
Results: Anti-Lectin-EGF antibody significantly reduced global crescent formation, tubulointerstitial injury and
improved renal function impairment through inhibiting DC maturation and modulating Foxp3 expression and the
Th1/Th2 cytokine balance in kidney. Binding of anti-Lectin-EGF antibody to DC-SIGN on human DCs inhibited DC
maturation, increased IL-10 production from DCs and enhanced CD4+CD25+ Treg functions.
Conclusions: Our results suggest that treatment with anti-Lectin-EGF antibody modulates DCs to suppressive DCs
and enhances Treg functions, contributing to the attenuation of renal injury in a rat model of nephrotoxic
nephritis.
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Glomerulonephritis (GN) is a common cause of renal fail-
ure. Tubulointerstitial inflammation is a major contribu-
tor of GN progression to renal failure, even in crescentic
GN with severe glomerular injury [1,2]. Evidences suggest* Correspondence: zhoutong_cn@hotmail.com
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reproduction in any medium, provided the orthat crescent formation is driven by Th1-dominated
nephritogenic immune responses [3-6]. Development of
Th1 or Th2 immunity is controlled by dendritic cells
(DCs). In different forms of GN, renal function and prog-
nosis closely correlate with the extent of DC infiltration
into the tubulointerstitium [7-9].
DCs are critical in the control of immune responses and
homoeostasis. Mature DCs induce Th1, Th2 and Th17 ef-
fector T-cells, whereas immature DCs drive the develop-
ment of regulatory T cells (Tregs), which maintain tolerance
to self-antigens and inhibit excessive immune responses by. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pathogen-specific and exhibits a large degree of plasticity
[15]. The nature of the antigen determines the balance to-
wards immunity or tolerance. DCs express a large array of
cell surface lectins and lectin-like molecules which are re-
ceptors for cognate antigens [16-20]. DC-specific intercellu-
lar adhesion molecule-3-grabbing non-integrin (DC-SIGN),
a member of the C-type lectin family, mediates DC adhesion
and migration, inflammation, activation of primary T cells,
contributes to immune responses and the immune escape
of pathogens and tumors [21-23]. DC-SIGN is abundantly
expressed on immature DCs (iDCs) and is down-regulated
during maturation [21]. DC-SIGN signaling can induce op-
posite immune responses [18,22,24]. Ligation of DC-SIGN
on DCs actively primes DCs to induce Tregs [25]. Thus,
targeting DC-SIGN may be a useful strategy to suppress in-
flammatory responses, which could be beneficial in man-
aging autoimmunity.
Previously we demonstrated that DCs treated in vitro with
an anti-lectin-EGF domain monoclonal antibody originally
developed against P-selectin (PsL-EGFmAb) displayed low
expression of co-stimulatory molecules and an impaired
capability to stimulate CD4+ T cells [26], indicating suppres-
sion of DC maturation and function. However, the under-
lying mechanism remains unclear. Thus, we administered
PsL-EGFmAb to a rat model of nephrotoxic nephritis (NTN),
an immune-mediated animal model of human crescentic
GN, to investigate whether PsL-EGFmAb could affect DC
maturation and Treg- and Th1/Th2-related gene expression
in renal tissues, and further investigate the mechanism by
which this antibody affects DCs in vitro. We infer that PsL-
EGFmAb might interact with DC-SIGN that also contains a
lectin domain to inhibit DCmaturation and induceTregs that
inhibit effector T cell functions. Our results showed that a
lectin-EGF antibody targeting DC-SIGN on dendritic cells
promotes regulatory T cells and attenuates nephrotoxic
nephritis.
Methods
Animals and treatment protocol
Male 6-8-week old Wistar-Kyoto rats were bred and kept
in specific-pathogen-free conditions in an animal facility.
Rabbit nephrotoxic serum was generated as described pre-
viously [27,28]. The amount of nephrotoxic serum per
gram of body weight used in this study (2.0 or 2.5 mg im-
munoglobulin per gram body weight) was within the linear
range of a dose response. Eighteen rats were equally and
randomly assigned to three groups and received different
injection by tail vein: control group rats injected with nor-
mal rat serum; NTN group rats injected with two doses of
mouse IgG (2 μg per gram of rat body weight) at 0 and 2 h
after nephrotoxic serum injection; PsL-EGFmAb-treated
group rats received two injections of PsL-EGFmAb, a
mouse anti-human monoclonal antibody established in ourlab (2 μg per gram of rat body weight) at 0 and 2 h after
nephrotoxic serum injection. On day 14, the rats were
anesthetized with ketamine and sacrificed. Rats in every
group were placed in metabolic cages to collect 24 hours
urine and detect urine creatinine. Blood was got from
inner canthal vein of rats in every group. Serum creatintine
(Scr) and urea nitrogen were detected by automatic bio-
chemical analyzer. Creatinine clearance rate (CCr) was got
by the formula according to creatintine and urine output
in serum and urine. The kidneys were quickly isolated and
fixed in 10% buffered formaldehyde. The study was
approved by the Ethics Committee of Ruijin Hospital,
Shanghai Jiaotong University School of Medicine.
Renal function studies
For urine sample collection, rats were housed in meta-
bolic cages. Albuminuria was determined by standard
ELISA analysis. Blood samples for blood urea nitrogen
(BUN) measurement were obtained at the time of sacri-
fice. Scr and BUN were measured by standard laboratory
methods. Ccr (ml/min) was used to estimate glomerular
filtration rate (GFR).
Periodic Acid Schiff staining
To evaluate glomerular and tubulointerstitial injury,
formalin-fixed rat renal tissue was embedded in paraf-
fin, sectioned at 4 μm, and stained with Periodic Acid
Schiff (PAS) for histological analysis. Tubulointerstitial
lesions were scored as follows: 0, no tubular damage, no
interstitial edema; 0.5, thinning of the brush borders; 1,
thinning of the tubular epithelial; 2, denudation of the
tubular basement membrane; 3, tubular necrosis.
Analysis of MHC class-II, DC-SIGN and CD80 expressed on
renal DCs
DCs were isolated from rat kidneys as previously de-
scribed [29]. Briefly, kidneys were finely minced and
digested for 45 min at 37°C with 2 mg/ml collagenase D
in RPMI 1640 medium with 10% heat-inactivated fetal
calf serum. Cell suspensions were filtered through 30
μm nylon mesh, and washed with HBSS without Ca2+
and Mg2+ containing 10 mmol/L EDTA, 0.1% BSA and
10 mM Hepes. Density centrifugation was performed at
1700 × g for 20 min at 4°C using 1.080 g/ml of Nycodenz
(Axis-Shield). The interphase cells were harvested and
isolated with anti-rat OX62 micro-beads (Miltenyi Biotec,
Bergisch Gladbach, Germany). Isolated cells (5 × 105) were
stained with FITC- and PE-labeled mAbs specific for
MHC class-II and CD80. In addition, 1 × 105 DCs were
stained indirectly with DC-SIGN using goat anti-rat DC-
SIGN polyclonal antibody and PE-conjugated donkey
anti-goat IgG mAb. Phenotypic analysis was performed by
flow cytometry using a FACS Calibur (BD FACSAria™Cell
Sorter).
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Renal tissue was lysed and total RNA extracted using
Trizol reagent (Invitrogen, Carlsbad, CA, USA). cDNA
was synthesized using the RevertAid First Strand cDNA
Synthesis Kit (Fermentas, Burlington, Canada), following
the manufacturer’s recommendations. The cycle number
at which the fluorescence increased above the threshold
was designated as the threshold cycle (CT). Primer spe-
cificity was assessed by melting curve. These samples
were then analyzed for the expression of IFN-γ, TNF-α,
IL-6, IL-4, Foxp3, IL-10, TGF-β, and GAPDH genes by
PCR using the SYBR GREEN PCR Master Mix (Applied
Biosystems, Carlsbad, CA, USA) and the ABI PRISM
7700 Sequence Detection System. The sequences of the
specific primer pairs used in each case were listed in
Table 1. PCR was performed three times as follows: 40
cycles of denaturing at 95°C for 15 s and annealing/ex-
tension at 60°C for 1 min. Results were normalized to
GAPDH expression using the 2–ΔΔCt method.
Cell isolation
PBMCs were obtained from whole blood of healthy donors
by Ficoll density gradient centrifugation (Sigma-Aldrich,
St. Louis, MO, USA). Then, monocytes were isolated by
positive selection with human anti-CD14 microbeads
(Miltenyi Biotec), following the manufacturer’s instruc-
tions. To generate imDCs, isolated CD14+ monocytes (5 ×
105/ml) were incubated at 37°C for 5–7 days in RPMI 1640
complete medium (Invitrogen), containing 10% fetal calf
serum and supplemented with 50 ng/ml human GM-CSF
and 20 ng/ml human IL-4 (R&D Systems). To obtain
mDCs, imDCs were incubated for 48 h in the presence of
50 ng/ml TNF-α (R&D Systems). PsL-EGFmAb (10 μg/ml)
was added to the culture 2 h before TNF-α addition to ob-
tain PsL-EGFmAb-treated DCs. The expression of HLA-
DR, CD80, CD86, CD83 and DC-SIGN on the surface of
DCs was confirmed by flow cytometry analysis.
Human CD4+ T cells were isolated from PBMCs by
negative selection and the fraction of remaining cells were
used to further isolate CD4+CD25- T and CD4+CD25+ T
cells by negative and positive selection using a humanTable 1 Sequences of specific primer pairs
Forward







GAPDH 5′-AGGACCAGGTTGTCTCCTGT −3′CD4+CD25+ Treg isolation kit (Miltenyi Biotec), following
the manufacturer's instructions.
Flow cytometry analysis
Expressions of surface antigens on DCs (1 × 105) were
assessed with the following mAbs: anti-human HLA-DR
and CD83, PE-labeled anti-rat CD80, anti-human CD80
and DC-SIGN, allophycocyanin-labeled anti-human CD86,
goat anti-rat DC-SIGN antibody and PE-conjugated don-
key anti-goat IgG. Appropriate isotype antibodies were
used as controls. The proportion of CD4+CD25+Foxp3+ T
cells in the CD4+ T cell population was determined using a
human Treg staining kit (eBioscience), according to manu-
facturer’s instructions. In brief, after CD4 and CD25 sur-
face staining, cells (5 × 105) were washed and fixed at 4°C
for 60 min in the dark using fixation/permeabilization so-
lution. Cells were then stained intracellularly for Foxp3.
To investigate whether PsL-EGFmAb can bind to DC-
SIGN, flow cytometry analysis was performed. First, we
used PE-labeled anti-DC-SIGN mAb and PsL-EGFmAb
together with FITC-labeled anti-mouse IgG mAb to
detect expression of DC-SIGN on imDCs (1 × 105) sep-
arately. Then imDCs were incubated with goat anti-
human DC-SIGN antibody for 2 h before detection of
DC-SIGN expression by PsL-EGFmAb together with FITC-
labeled anti-mouse IgG mAb. The percentage of positive
cells was analyzed in a FACSCalibur flow cytometer
(BD Biosciences), using Flowjo software (v. 5.7.2, Tree
Star Inc., Ashland, OR, USA).
Cytokine assays
Levels of IFN-γ, IL-12, TGF-β, IL-10 and IL-6 in cell
cultures were determined by ELISA (Biosource, Carlsbad,
CA, USA). Briefly, cell culture supernatants were collected
and the cytokine concentration was analyzed by a specific
solid phase sandwich enzyme immunoassay, following the
manufacturer’s instructions.
Allogeneic mixed cell proliferation assays
The ability of DCs to stimulate CD4+ T cells was assayed
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cells by magnetic bead-labeled anti-rat CD4 mAb
(Miltenyi Biotec) were incubated with irradiated (30 Gy)
DCs (2 × 104) isolated from rat kidneys in control, NTN
and PsL-EGFmAb-treated groups with anti-rat OX62
micro-beads as mentioned above at a 10:1 ratio in a 96-well
U-bottomed plate at 37°C for five days. T cell proliferation
was assessed after five days of co-culture by [methyl-3H]
thymidine ([3H]TdR, 5.0 μCi/ml) incorporation in a 16-h
pulse. For this purpose, cells were harvested with a semi
automated device, and the incorporation of [3H]TdR was
determined in a liquid scintillation counter. Triplicate wells
were cultured for each group.
To analyze the stimulatory potential of human DCs on
allogeneic CD4+ T, CD4+CD25+ T and CD4+CD25- T cells,
T cells (2 × 105) were co-cultured for five days with imDCs,
mDCs or PsL-EGFmAb-treated DCs (2 × 104). T cells with-
out DC or PsL-EGFmAb treatment were used as a control.
T cell proliferation was assessed as mentioned above. All of
these experiments were conducted in triplicate.
Suppression assays
To analyze the suppressive function of the Tregs in-
duced in vitro by DCs, autologous mixed cell cultures
were performed [30]. Briefly, CD4+CD25+ T cells recov-
ered after five days of co-culture with DCs (T1 cells),
were maintained in culture for two additional days in
the presence of IL-2 (50 U/ml) (R&D Systems). T1 cells
or MACS freshly isolated normal human CD4+CD25+
Tregs (2 × 105) were mixed with autologous CD4+
CD25- T cells (1 × 105) and stimulated with anti-CD3
(5 μg/ml) mAb plus anti-CD28 (1 μg/ml) mAb. After
two days of cell culture, 5.0 μCi/ml [3H]TdR was added
and the cells were harvested 16 h later. Results were
expressed as fold increases in [3H]TdR incorporation.
Neutralization assays
To determine which cytokines secreted by PsL-
EGFmAb-treated DCs were involved in CD4+CD25+ Treg
priming, anti-IL-6 (5 μg/ml), anti-IL-10 (10 μg/ml), anti-
TGF-β (10 μg/ml), anti-IL-4 (10 μg/ml), anti-TNF-α (5 μg/
ml), anti-IL-12 (10 μg/ml) and anti-IFN-γ (5 μg/ml) mAbs
were used. PsL-EGFmAb-treated DCs (2 × 104) were co-
cultured with MACS freshly isolated human CD4+CD25+
T cells (2 × 105) for five days in the presence of the different
neutralizing antibodies mentioned above. Mouse IgG was
also added as an isotype control. CD4+CD25+ T cells alone
were used as a negative control. T cell proliferation was
assessed by [3H]TdR (5.0 μCi/ml) incorporation in a 16-h
pulse. Cells were harvested with a semi automated device,
and the incorporation of [3H]TdR was determined in a
liquid scintillation counter.
Next, to determine which cytokines secreted by T1 cells
inhibited CD4+CD25- effector T cell proliferation, the sameneutralizing antibodies at similar doses were used. PsL-
EGFmAb-treated DC-induced T1 cells (2 × 105) were
co-cultured with 1 × 105 MACS freshly isolated human
CD4+CD25- T cells for five days in the presence of different
neutralizing antibodies. Mouse IgG was also added as an
isotype control, while CD4+CD25- T cells alone were used
as a negative control. T cell proliferation was assessed using
the method mentioned above. All of these experiments
were conducted in triplicate and the results were expressed
as fold increases in [3H]TdR incorporation.
siRNA Sequences (DC-SIGN)
Sequences of various siRNAs used are as follows: DC-
SIGN antisense, 5′-ATT TGT CGT CGT TCC AGC
CAT-3′; DC-SIGN sense, 5′-ATG GCT GGA ACG
ACA CAA A-3′; DC-SIGN antisense scrambled control,
5′-CAC ACC ACA TCT TTC CGT CAC-3′; DC-SIGN
sense scrambled control, 5′-GTG ACG GAA AGA TGT
GGT G-3′. RNA oligonucleotides were custom synthe-
sized by Dharmacon Research Inc (Lafayette, CO, USA)
with an overhang of 2 thymidine residues (dTdT) at the
3′ end. The RNA oligonucleotides were dissolved in
Tris-EDTA (10 mM Tris–HCl, pH 8.0; and 1 mM
EDTA) as 200 μM solutions and were stored at −20°C.
Double-stranded siRNA molecules were generated by
mixing the corresponding pair of sense and antisense
RNA oligonucleotides in annealing buffer (30 mM
HEPES-KOH, pH 7.9; 100 mM potassium acetate; and 2
mM magnesium acetate) at 20 μM and then by incubat-
ing the reaction mixture at 95°C for 2 min, followed by
gradual cooling to room temperature. The siRNAs were
then aliquoted and stored at −20°C.
Transfection of siRNAs
Twenty-four-hours before siRNA transfection, DCs (1 × 106)
were seeded in 6-well plates in OPTI-minimal essentials
medium (OptiMEM; Invitrogen, Grand Island, NY, USA)
containing 10% fetal bovine serum (FBS) with no antibiotics.
Cells were seeded per 6-well plate to give 30% to 50%
confluency at the time of the transfection. The siRNAs were
transfected at a final concentration of 50 nM using
Oligofectamine (Invitrogen) according to the manufacturer’s
recommendations. The control (untransfected) cells re-
ceived either Oligofectamine alone or Oligofectamine plus
scrambled sequence. The siRNAs added to control cells
were incubated for 24–48 and 72 hours and the cells were
harvested and RNA was extracted.
Immunoprecipitation
ImDCs (5 × 105) were lysed in lysis buffer (1% Triton-X-
100, 10 mM TEA pH 8.2, 150 mM NaCl, 1 mM MgCl2
and 1 mM CaCl2) containing a cocktail of EDTA-free
protease inhibitors for 1 h at 4°C. Cell lysates were
immunoprecipitated with PsL-EGFmAb-coated or mouse
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USA), following the manufacturer's instructions. Briefly,
cell lysates were incubated with PsL-EGFmAb-coated or
mouse IgG-coated beads overnight at 4°C on an orbital
shaker. The beads were then collected and washed three
times with 800 μl of ice-cold PBS followed by pulse centri-
fugation. After washing, beads were resuspended in 60 μl
of 2 × sample buffer and gently mixed. DC-SIGN was
detected by western blotting using the protocol mentioned
above. Cell lysates without immunoprecipitation were used
as positive controls.
Statistical analysis
SPSS software, version 11.0, was used for statistical ana-
lyses. Data are presented as the mean ± SD. Statistically
significant differences between groups were determined
using the Student’s t test or Mann–Whitney U-test, as ap-
propriate. A value of p < 0.05 was considered significant.
Results
PsL-EGFmAb treatment attenuates renal lesions and
improves renal function in a rat model of NTN
A rat model of NTN was established and used to test the
therapeutic effect of PsL-EGFmAb [31]. Rats injected with
nephrotoxic serum developed typical NTN inflammation
on day 14 after induction, characterized by enlargedFigure 1 Effect of PsL-EGFmAb on renal pathology and function. A, P
(final magnification × 200). Renal tissues were harvested on day 14. B, Tubuloi
mentioned in the Methods. C-F, Twenty-four-hour urine proteins (C), Scr (D) a
levels were significantly reduced on day 14 compared with non-nephritic con
-hour urine proteins (C), Scr (D), BUN (E) levels and increased CCr (F) compare
after PsL-EGFmAb treatment. The mean ± SD of three independent experimeglomeruli, global cellular crescent formation in more than
50% of glomeruli (59.41 ± 2.22%, p < 0.01) destruction of
Bowman's capsule wall, abruption of the basement
membranes of glomeruli and tubules, interstitial edema
and diffuse inflammatory cell infiltration (Figure 1A).
Compared to control rats injected with IgG, rats treated
with PsL-EGFmAb showed attenuated glomerular and
tubulointerstitial lesions (Figure 1A and 1B). The propor-
tion of glomeruli with crescent formation was significantly
reduced (33.90 ± 6.46%, p < 0.01).
Twenty-four-hour urinary proteins (Figure 1C), Scr
(Figure 1D) and BUN (Figure 1E) of nephritic rats were
significantly elevated, and Ccr (Figure 1F) was significantly
decreased on day 14 compared with non-nephritic controls
(p < 0.01). In the PsL-EGFmAb-treated group, we observed
a significant reduction in levels of urinary 24-hour proteins,
BUN and Scr, and increased Ccr levels compared with the
NTN group (p < 0.01), indicating that PsL-EGFmAb treat-
ment improved renal function.
PsL-EGFmAb treatment inhibits renal DC maturation
To investigate whether treatment of PsL-EGFmAb could
inhibit DC maturation in vivo, renal DCs were freshly iso-
lated at two weeks. Injection of rats with rabbit nephro-
toxic serum significantly up-regulated MHC class-II and
CD80 expression but down-regulated DC-SIGN expressionAS staining of renal tissues and corresponding quantification
nterstitial damage was evaluated according to the scoring system we
nd BUN (E) of nephritic rats were significantly elevated, whereas CCr (F)
trols (p < 0.01). PsL-EGFmAb treatment significantly reduced twenty-four
d with NTN group (p < 0.01), indicating improvement of renal function
nts is shown. **p < 0.01 vs. control; #p < 0.05, ##p < 0.01 vs. NTN group.
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PsL-EGFmAb significantly down-regulated DC-SIGN and
CD80 expression and slightly decreased MHC class-II ex-
pression on DCs compared with controls treated with
non-specific IgG. DC-SIGN expression was decreased after
treatment with PsL-EGFmAb (Figure 2, A-C). The abilityFigure 2 Effect of PsL-EGFmAb on renal DC maturation. A-C, Renal DC
isolated by MACS using anti-rat OX62 micro-beads on day 14 and maturity of
expression of MHC class-II, CD80 and DC-SIGN (black line). The isotype-match
reactions were used to evaluate the proliferation of CD4+ T cells induced by i
control, NTN and PsL-EGFmAb-treated groups were co-cultured with CD4+ T
assessed by [3H]TdR incorporation. The results were shown as fold increases in
experiments is shown. **p < 0.01 vs. control; ##p < 0.01 vs. NTN group.of DCs from the rat NTN group to stimulate T cells
significantly improved but was reduced in the PsL-
EGFmAb-treated group (Figure 2D). This suggests
that PsL-EGFmAb treatment significantly inhibited
DC-SIGN expression and DC maturation in the rat
NTN group.s from control (A), NTN (B) and PsL-EGFmAb (C) groups were freshly
DCs was determined by flow cytometry detected by cell surface
ed controls are shown as gray line. D, Allogeneic mixed lymphocyte
solated DCs. MACS-isolated and irradiated DCs from rat kidneys of
cells from healthy rats at a 1:10 ratio for five days. T cell proliferation was
[3H]TdR incorporation. The mean ± SD of three independent
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expression, shifts the Th1/Th2 cytokine profile and up-
regulates Treg-related gene expression in renal tissues
We measured the expression of three pro-inflammatory cy-
tokines, interferon (IFN)-γ (Figure 3A), tumor necrosis fac-
tor (TNF)-α (Figure 3B) and interleukin (IL)-6 (Figure 3C)
in renal tissues by real-time PCR. Administration of rabbit
nephrotoxic serum to rats induced significant expression of
all three cytokines compared with controls (p < 0.05).
Interestingly, the expression of all three cytokines was sig-
nificantly decreased in rats treated with PsL-EGFmAb com-
pared rats from the NTN group (p < 0.05), indicating that
PsL-EGFmAb elicits an anti-inflammatory effect in the rat
NTN model.
We next investigated the Th1/Th2 cytokine profile.
Non-immunized rats displayed a Th2-dominated cytokine
profile characterized by higher levels of IL-4 (Figure 3D)
compared to IFN-γ. Although injecting rats with rabbit
nephrotoxic serum induced significant IL-4 and IFN-γ se-
cretion (p < 0.05), the increase in IFN-γ expression was
much higher than IL-4, indicating a switch from a Th2- to
a Th1-dominated profile (Figure 3A, D, H). Interestingly,
PsL-EGFmAb treatment not only decreased IFN-γ expres-
sion, but also reversed the IFN-γ/IL-4 ratio compared
with the rat NTN group (Figure 3A, D, p < 0.05).
It is well established that Tregs can inhibit both Th1 and
Th2 type immune responses. To further explore the cause
of decreased levels of inflammatory cytokines after PsL-Figure 3 The mRNA expression of cytokines in renal tissues. Real-time
(G) mRNA expression and IFN-γ/ IL-4 ratio (H) in renal tissues. Expression o
described as 2–ΔΔCt. The mean ± SD of four independent experiments is shEGFmAb treatment, we investigated the expression of
Treg-related factors such as Foxp3, IL-10 and TGF-β in
renal tissues. There was a significant down-regulation of
Foxp3 expression (Figure 3E) after rats were injected with
the rabbit nephrotoxic serum (p < 0.05), whereas PsL-
EGFmAb treatment significantly up-regulated Foxp3 ex-
pression in both the NTN group and non-immunized rats
(p < 0.05), indicating the possible up-regulation of Tregs
after PsL-EGFmAb treatment. We then examined ex-
pression of IL-10 and TGF-β, the two main cytokines
promoting Treg priming. Injecting rats with rabbit
nephrotoxic serum significantly up-regulated IL-10 expres-
sion (Figure 3F) (p < 0.05), and PsL-EGFmAb treatment
further increased IL-10 expression compared with the
NTN group (p < 0.05). There was no significant difference
in TGF-β expression among the three groups (Figure 3G).
Together, these results suggest that PsL-EGFmAb treat-
ment in the rat NTN model enhanced Treg function, and
that IL-10 expression might be involved.
PsL-EGFmAb inhibits human DC maturation in vitro
The in vivo data above suggested that alleviation of in-
flammation resulting from PsL-EGFmAb treatment was
associated with a reversed Th1/Th2 cytokine profile, and
was potentially the result of Treg up-regulation. DCs de-
termine differentiation of Th0 cells to Th1 or Th2 pheno-
type. DCs at different maturation stages have different
roles in T cell differentiation [32]. To further probe thePCR for IFN-γ (A), TNF-α (B), IL-6 (C), IL-4 (D), Foxp3 (E), IL-10 (F), TGF-β
f the genes of interest was normalized to that of the GAPDH gene, and
own. *p < 0.05, **p < 0.01 vs. control; #p < 0.05, ##p < 0.01 vs. NTN group.
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affects T cell functions, we used an in vitro system and in-
vestigated whether PsL-EGFmAb could affect DC matur-
ation. As shown in Figure 4, A-C, flow cytometric analysis
revealed that PsL-EGFmAb-treated DCs exhibited lower
expression of CD80, CD86 and CD83 compared with
TNF-α-induced mature DCs (mDCs). There was no dif-
ference in human leukocyte antigen (HLA)-DR expression
between DCs with or without PsL-EGFmAb treatment
(Figure 4, A-C).
PsL-EGFmAb treatment promotes Treg priming mediated
by DCs in vitro
To further investigate the effect of PsL-EGFmAb on DC-
mediated T cell priming, CD4+ T cells, CD4+CD25+ TregsFigure 4 PsL-EGFmAb inhibits human DC maturation in vitro. Human
method and cultured in RPMI 1640 complete medium in the presence of 5
produce imDCs. mDCs were induced by further treatment with 50 ng/ml T
before TNF-α treatment. Expression of HLA-DR, CD80, CD83 and CD86 on i
cytometry. A, imDCs. B, mDCs. C, PsL-EGFmAb-treated DCs (black line). App
were representative of at least three independent experiments.and CD4+CD25- T cells were freshly isolated from human
peripheral blood mononuclear cells (PBMCs) of healthy
adults using MACS. Isolated T cells were co-cultured with
imDCs, mDCs or TNF-α plus PsL-EGFmAb-treated DCs.
Allogeneic mixed cell proliferation assays revealed that
imDCs slightly increased the proliferation of all three types
of T cells. In contrast, mDCs significantly increased prolif-
eration of both CD4+ T cells and CD4+CD25– effector T
cells, but failed to increase CD4+CD25+ Treg proliferation
compared with imDCs. Interestingly, PsL-EGFmAb-treated
DCs displayed totally different characteristics to mDCs.
PsL-EGFmAb-treated DCs significantly promoted CD4+
CD25+ Treg proliferation and inhibited any further
increase in CD4+ T cell and CD4+CD25– effector T cell
proliferation (p < 0.05) (Figure 5, A-C). Flow cytometricCD14+ monocytes from healthy donors were isolated using the MACS
0 ng/ml human GM-CSF and 20 ng/ml human IL-4 for five days to
NF-α. In PsL-EGFmAb group, 10 μg/ml PsL-EGFmAb was also added
mDCs, mDCs, or PsL-EGFmAb-treated DCs was detected by flow
ropriate isotype antibodies were used as controls (gray line). Data
Figure 5 Allogeneic mixed T cell proliferation assays. imDCs, mDCs or PsL-EGFmAb-treated mDCs were co-cultured with freshly isolated human
CD4+, CD4+CD25+ and CD4+CD25– T cells, respectively, then proliferation assays were performed and the results are shown as fold increases in [3H]TdR
incorporation. Flow cytometric analysis was also performed to detect CD4+CD25+Foxp3+ Tregs. A, DCs co-cultured with CD4+ T cells. B, DCs co-cultured
with CD4+CD25+ T cells. C, DCs co-cultured with CD4+CD25– T cells. D, A suppression assay was performed to evaluate the suppressive function of CD4
+CD25+ T cells using the same method. Tregs were either co-cultured with PsL-EGFmAb-treated mDCs (T1) or freshly isolated from health adults. The
mean ± SD of four independent experiments is shown. #p < 0.05, ##p < 0.01.
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increased the percentage of CD4+CD25+Foxp3+ Tcells after
co-culture with CD4+ T cells (Figure 5A). CD4+CD25+Foxp3+
T cells were almost undetectable when DCs were co-cultured
with CD4+CD25- effector Tcells (Figure 5C).
Next, we investigated whether proliferating CD4+CD25+
Tregs after co-culture with PsL-EGFmAb-treated DCs (T1
cells) could exhibit the same suppressive function as
freshly isolated CD4+CD25+ Treg cells. Both T1 cells
and freshly isolated CD4+CD25+ Treg cells significantly
inhibited CD4+CD25– effector T cell proliferation (p <
0.05) determined by suppression assay, indicating T1 cells
and freshly isolated CD4+CD25+ Treg cells exhibited the
same suppressive function (Figure 5D).
IL-10 secreted by PsL-EGFmAb-treated DCs contributes to
induction of Tregs
To investigate whether cytokines secreted by DCs were in-
volved in the priming of Tregs, an enzyme-linked immuno-
sorbent assay (ELISA) assay and neutralizing assay were
performed. First we detected cytokines secreted by DCs
subjected to different treatments. All DCs, despite differ-
ences in treatments, secreted low levels of IFN-γ (Figure 6A)
and moderate levels of TGF-β (Figure 6E). There were noFigure 6 Assays to analyze the cytokines involved in DC maturation.
(E) using the culture supernatants of imDCs, mDCs (TNF-α-treated DCs) and T
PsL-EGFmAb-treated DCs were co-cultured with freshly isolated CD4+CD25+ T
anti-human antibodies in vitro: anti-IL-6, anti-IL-10, anti-TGF-β, anti-IL-4, anti-TN
also used. Allogeneic mixed T cell proliferation assays were performed as abo
G, Neutralization assays. CD4+CD25+ T cells were co-cultured with PsL-EGFmA
Suppression assays were performed in the presence of the neutralizing antibo
three independent experiments is shown. *p < 0.05, **p < 0.01 vs. control; #p <significant differences among these groups (p > 0.05). mDCs
secreted much higher levels of IL-12 (Figure 6B) and IL-6
(Figure 6C) compared with imDCs (p < 0.05). However,
PsL-EGFmAb treatment dramatically reduced IL-6 secre-
tion (p < 0.05) but not IL-12. Although mDCs also secreted
IL-10 compared with imDCs (p < 0.05), treatment of mDCs
with PsL-EGFmAb significantly increased IL-10 secretion
(Figure 6D) (p < 0.05). These results suggested that changes
in cytokine production following PsL-EGFmAb treatment
might be involved in Treg cell priming.
Next we used neutralizing antibodies to block the ac-
tion of cytokines secreted by DCs to determine which
cytokines were involved in Treg cell priming. Freshly
isolated CD4+CD25+ Treg cells were co-cultured with
PsL-EGFmAb-treated DCs in the presence of different neu-
tralizing antibodies. CD4+CD25+ Treg cell proliferation was
significantly inhibited in the presence of anti-IL-10 neutral-
izing antibody, whereas anti-IL-6, anti-TGF-β, anti-IL-4,
anti-TNF-α, anti-IL-12 and anti-IFN-γ mAbs failed to in-
hibit cell proliferation, indicating that IL-10 was the key
cytokine for Treg cell priming (Figure 6F).
A suppression assay confirmed these results. CD4+CD25+
T cells were co-cultured with PsL-EGFmAb-treated DCs
for two days before freshly isolated CD4+CD25- T cells wereA-E, ELISA assay for IFN-γ (A), IL-12 (B), IL-6 (C), IL-10 (D) and TGF-β
NF-α with PsL-EGFmAb-treated DCs in vitro. F, Neutralization assays.
regs only (control) or in the presence of one of the following neutralizing
F-α, anti-IL-12 or anti-IFN-γ mAbs. The isotype-matched controls were
ve. The results are shown as fold increases in [3H]TdR incorporation.
b-treated mDCs (T1 cell), then mixed with CD4+CD25- effector T cells.
dies mentioned above or with medium only (control). The mean ± SD of
0.05, ##p < 0.01 vs. mDC group; +p < 0.05, ++p < 0.01 vs. imDC group.
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Compared to the isotype IgG-treated group, co-cultured
CD4+CD25+ T cells failed to inhibit CD4+CD25- T cell pro-
liferation in the presence of anti-IL-10 neutralizing anti-
body, whereas anti-IL-6, anti-TGF-β, anti-IL-4, anti-TNF-α,
anti-IL-12 and anti-IFN-γ mAbs had no significant effect
on cell proliferation (Figure 6G), indicating that IL-10 was
involved in supporting the suppressive function of Tregs.
PsL-EGFmAb targets DCs through DC-SIGN
Our data indicate that PsL-EGFmAb treatment could affect
DC maturation and function, subsequently affecting
Treg priming and function. Next, we investigated how
PsL-EGFmAb signaled to DCs. We measured DC-
SIGN expression on imDCs by flow cytometry using
fluorescence-labeled DC-SIGN mAb and PsL-EGFmAbFigure 7 PsL-EGFmAb signals to DCs through DC-SIGN. A-C, We gener
monocytes from healthy donor blood with GM-CSF and IL-4 for 5 days (imDCs)
fluorescence-labeled DC-SIGN mAb (A) and PsL-EGFmAb (B) respectively. C, imD
prevent binding of PsL-EGFmAb to DCs before staining with PsL-EGFmAb. D, W
immunoprecipitated using PsL-EGFmAb-coated beads (left), imDC lysates witho
mouse IgG-coated beads (right). Experiments were performed in triplicate and t
analysis of DC-SIGN from different samples: The lysates of imDCs with DC-SIGN
lysates of imDCs with DC-SIGN siRNA without immunoprecipitation (middle), th
IgG-coated beads (right).respectively. We also pre-incubated imDCs with anti-DC-
SIGN goat antiserum to prevent binding of PsL-EGFmAb
to DCs before staining with fluorescence labeled-PsL-
EGFmAb. A similar percentage of positive cells were
detected with both mAbs (Figure 7, A-C). Pre-incubation
of DCs with anti-DC-SIGN goat antiserum to block DC-
SIGN on DCs before detection, dramatically reduced the
number of positive cells, indicating that PsL-EGFmAb
likely binds to DC-SIGN on DCs.
To confirm this, immunoprecipitation was performed.
DCs with or without DC-SIGN siRNA were lysed, and DC
lysates immunoprecipitated with PsL-EGFmAb-coated
beads. DC-SIGN was detected in immunoprecipitated DC
lysates, similar to the positive control. This further sup-
ported the interaction between PsL-EGFmAb and DC-
SIGN (Figure 7D, E).ated human monocyte-derived DCs by incubating MACS-isolated CD14+
. Flow cytometry detected DC-SIGN expression on imDCs using
Cs pre-incubated with anti-DC-SIGN goat antiserum were also included to
estern blotting analysis of DC-SIGN in different samples: imDC lysates
ut immunoprecipitation (middle), imDC lysates immunoprecipitated using
he data from one representative experiment is shown. E, Western blotting
siRNA were immunoprecipitated using PsL-EGFmAb-coated beads (left), the
e lysates of imDCs with DC-SIGN siRNA immunoprecipitated using mouse
Cai et al. Journal of Translational Medicine 2013, 11:103 Page 12 of 14
http://www.translational-medicine.com/content/11/1/103Discussion
NTN is an animal model of human crescentic GN, char-
acterized by glomerular crescent formation, tubulo-
interstitial inflammation, impaired renal function and
proteinuria [1,2,33]. Several studies demonstrated that a
Th1-dominated nephritogenic immune response is re-
sponsible for the formation of crescents [1,2]. Recently,
the protective role of Tregs in GN has been demon-
strated [34]. It is well established that DCs play a critical
role in the development of tubulointerstitial inflamma-
tion by modulating Th0 cells to Th1, Th2 or Th17
polarization [35], or limiting inflammation by promot-
ing Tregs [36].
In the present study, we demonstrated that treatment
with PsL-EGFmAb led to a reversal of the Th1-dominated
cytokine mRNA expression profile and attenuation of renal
lesions in a rat model of NTN. This was accompanied by
improvement of renal function indicating that the protect-
ive effect likely involved the inhibition of DC maturation,
and subsequent T cell differentiation. DCs have an import-
ant role in peripheral tolerance by various mechanisms, in-
cluding activation of Tregs, induction of T cell anergy and
skewed Th1/Th2 differentiation [37,38]. Increasing evi-
dence suggests that DC functions are associated with mat-
uration status [39,40]. Fully matured DCs are efficient
activators of T cells, while imDCs have been implicated in
anergy induction [41]. An intermediate stage of DC matur-
ation was recently described, where DCs express relatively
high levels of MHC class-II and co-stimulatory molecules,
but do not secrete proinflammatory cytokines [42]. Previ-
ously we showed that treatment of DCs with PsL-EGFmAb
, an anti-lectin-EGF domain monoclonal antibody origin-
ally developed against P-selectin, led to suppression of DC
maturation and inhibition of CD4+ T cell proliferation
in vitro [24]. In the present study we further demonstrated
the suppression of DC maturation and T cell stimulation
after PsL-EGFmAb treatment ex vivo, and interestingly ob-
served an upregulation of Foxp3 and IL-10 expression in
renal tissues from rat NTN. Together, treatment of PsL-
EGFmAb inhibited DC maturation, which could in turn in-
duce Treg differentiation and regulate Th1/Th2 bias.
To further characterize the effect of PsL-EGFmAb on
DCs, we used human DCs that comprehensively reflected
DC maturation and functions. Our results suggested that
treating DCs with PsL-EGFmAb could drive DCs to an
intermediate maturation stage assessed by expression of
intermediate levels of co-stimulatory molecules. DCs at
this maturation stage may be capable of inducing immune
tolerance.
Promotion of Tregs is one mechanism by which DCs
regulate immune tolerance. We therefore investigated
whether PsL-EGFmAb-treated DCs could promote
CD4+CD25+ Treg development. PsL-EGFmAb-treated
DCs suppressed CD4+ T cell proliferation by stimulatingthe expansion of CD4+CD25+ Tregs. This raised the ques-
tion of whether PsL-EGFmAb-treated DCs promoted
CD25+ Treg proliferation or induced CD25+ Treg differ-
entiation from CD25– T cells. To address this question,
we sorted CD4+CD25– T cells and cultured them with
PsL-EGFmAb-treated DCs. PsL-EGFmAb-treated DCs
failed to differentiate CD4+CD25– cells into CD4+CD25+
Tregs, but stimulated the expansion of primary CD4+CD25+
Tregs. Furthermore, the expanded CD4+CD25+ Tregs
displayed the same ability to suppress T cell function as
freshly isolated CD4+CD25+ Tregs.
IL-10 and TGF-β are immunoregulatory cytokines
which facilitate the generation of murine and human
Tregs [32]. Chronic activation of murine and human
CD4+ T cells in the presence of IL-10 results in the
generation of Tregs [43]. When polarized, these cells
can inhibit in vitro and in vivo alloresponses [43]. In
the present study, the addition of neutralizing anti-IL-
10 mAb significantly inhibited CD4+CD25+ T cell pro-
liferation induced by PsL-EGFmAb-treated DCs, and
attenuated their suppressive function on CD4+CD25- T
cells. Antibodies against other cytokines had no effect,
indicating a critical role of IL-10 in the promotion of
Tregs by PsL-EGFmAb-treated DCs. Conversely, the
above phenomenon was not seen with neutralizing
anti-TGF-β mAbs.
According to the in vivo and in vitro data, we specu-
lated that PsL-EGFmAb treatment could inhibit DC
maturation in renal tissue or draining lymph nodes, to
induce the generation of tolerogenic DCs, which can in-
hibit Th1/Th2 polarization and promote Treg prolifera-
tion by IL-10. These events together could lead to the
alleviation of inflammation in renal tissue.
Next we determined which molecule on DCs interacted
with PsL-EGFmAb. As PsL-EGFmAb affected DC matur-
ation and function, this indicated that it might interact dir-
ectly with DCs. As DC-SIGN has a similar lectin domain to
P-selectin in its molecular structure, it may interact with
PsL-EGFmAb. To test this, we compared the binding of
PsL-EGFmAb and DC-SIGN mAb to DCs by flow cytome-
try, and found that both mAbs showed similar levels of
binding. Furthermore, DCs, in which DC-SIGN was
blocked by anti-DC-SIGN goat antiserum, led to dramatic-
ally reduced binding of PsL-EGFmAb. This was also sup-
ported by results from the immunoprecipitation study
using PsL-EGFmAb-labeled micro beads which clearly
showed that PsL-EGFmAb bound to DC-SIGN. Together,
our data clearly demonstrate that PsL-EGFmAb binds to
DC-SIGN on imDCs, although it can also bind to mole-
cules containing a lectin domain. Besides DC-SIGN, PsL-
EGFmAb might interact with other molecules possessing
lectin or EGF domains on DCs, contributing to the im-
mune regulation of DCs. All above are required further
studies to analyze such functions.
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Our findings revealed a potential regulatory effect of
PsL-EGFmAb, an anti-lectin-EGF domain monoclonal
antibody originally developed against P-selectin, on im-
mune responses including anti-inflammatory effects
and regulation of immune reaction through DC-SIGN
expressed by DCs. PsL-EGFmAb-treated DCs display an
immature profile, capable of promoting CD4+CD25+
Treg expansion and inhibiting CD4+ effector T cell pro-
liferation in vitro. The administration of PsL-EGFmAb
to a rat NTN model, attenuated renal immune lesions
accompanied by a skewed Th1/Th2 cytokine profile and
up-regulation of Treg-related Foxp3 expression, which
may have resulted from the generation of tolerogenic
DCs by PsL-EGFmAb treatment. Our results suggest
that PsL-EGFmAb could be a potential therapeutic
treatment for human kidney diseases.
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